.webp)
67/100B67.290
USD
-0.26
(-0.38%)
Post Trading·68.800USD+1.510(+2.24%)
Last updated: · Delayed 15 min
Fair value63.11Plus+7%48Price 67.2994
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Royalty Pharma shares outstanding 2015–2026What are shares outstanding? Shares outstanding are all the shares a company has issued that investors hold, insiders included. Their number times the share price is the market value.
Royalty Pharma had 445,265,805 shares outstanding on 9 November 2026. Royalty Pharma had 558.25M diluted shares on average over the last twelve months, down 2.4% on the twelve months before. In fiscal year 2025 the average was 559.61M.
Last updated 6 Nov 2026 · Next report 10 Feb 2027
Shares outstanding
Change on the year
| Fiscal year | Period ending | Shares outstanding | Change on the year | Basic shares |
|---|---|---|---|---|
| TTM | 30 Sept 2026 | 558.25M | -2.45% | 438.48M |
| FY2025 | 31 Dec 2025 | 559.61M | -5.79% | 431.89M |
| FY2024 | 31 Dec 2024 | 594.00M | -1.48% | 445.99M |
| FY2023 | 31 Dec 2023 | 602.90M | +6.72% | 447.60M |
| FY2022 | 31 Dec 2022 | 564.93M | +36.19% | 437.96M |
| FY2021 | 31 Dec 2021 | 414.80M | +6.87% | 414.79M |
| FY2020 | 31 Dec 2020 | 388.14M | +9.59% | 388.14M |
| FY2019 | 31 Dec 2019 | 354.18M | 0.00% | 354.18M |
| FY2018 | 31 Dec 2018 | 354.18M | 0.00% | 354.18M |
| FY2017 | 31 Dec 2017 | 354.18M | -41.65% | 354.18M |
| FY2016 | 31 Dec 2016 | 607.04M | 0.00% | 607.04M |
| FY2015 | 31 Dec 2015 | 607.04M | — | 607.04M |
| Quarter | Period ending | Shares outstanding | Growth on a year before | Basic shares |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 556.90M | -0.49% | 445.06M |
| Q2 FY2026 | 30 Jun 2026 | 556.90M | -0.96% | 445.06M |
| Q1 FY2026 | 31 Mar 2026 | 559.61M | -3.20% | 431.89M |
| Q4 FY2025 | 31 Dec 2025 | 559.61M | -4.99% | 431.89M |
| Q3 FY2025 | 30 Sept 2025 | 559.61M | -5.63% | 431.89M |
| Q2 FY2025 | 30 Jun 2025 | 562.30M | -5.80% | 423.51M |
| Q1 FY2025 | 31 Mar 2025 | 578.10M | -3.24% | 435.48M |
| Q4 FY2024 | 31 Dec 2024 | 589.00M | -2.16% | 445.99M |
| Q3 FY2024 | 30 Sept 2024 | 593.00M | -1.35% | 446.04M |
| Q2 FY2024 | 30 Jun 2024 | 596.91M | -1.48% | 451.02M |
| Q1 FY2024 | 31 Mar 2024 | 597.48M | -1.61% | 448.62M |
| Q4 FY2023 | 31 Dec 2023 | 602.02M | +15.19% | 448.02M |
| Q3 FY2023 | 30 Sept 2023 | 601.14M | -1.00% | 448.44M |
| Q2 FY2023 | 30 Jun 2023 | 605.86M | -0.22% | 450.41M |
| Q1 FY2023 | 31 Mar 2023 | 607.25M | +0.01% | 445.61M |
| Q4 FY2022 | 31 Dec 2022 | 522.61M | +2.27% | 441.79M |
| Q3 FY2022 | 30 Sept 2022 | 607.23M | +0.01% | 439.29M |
| Q2 FY2022 | 30 Jun 2022 | 607.21M | +0.01% | 436.32M |
| Q1 FY2022 | 31 Mar 2022 | 607.20M | +0.01% | 433.96M |
| Q4 FY2021 | 31 Dec 2021 | 510.99M | +31.65% | 421.51M |
| Q3 FY2021 | 30 Sept 2021 | 607.17M | +64.10% | 428.23M |
| Q2 FY2021 | 30 Jun 2021 | 607.16M | +71.52% | 409.34M |
| Q1 FY2021 | 31 Mar 2021 | 607.15M | +73.20% | 389.76M |
| Q4 FY2020 | 31 Dec 2020 | 388.14M | +10.15% | 388.14M |
| Q3 FY2020 | 30 Sept 2020 | 370.00M | +4.47% | 370.00M |
| Q2 FY2020 | 30 Jun 2020 | 353.98M | -0.06% | 353.98M |
| Q1 FY2020 | 31 Mar 2020 | 350.55M | -1.02% | 350.55M |
| Q4 FY2019 | 31 Dec 2019 | 352.37M | — | 352.37M |
| Q3 FY2019 | 30 Sept 2019 | 354.18M | — | 354.18M |
| Q2 FY2019 | 30 Jun 2019 | 354.18M | — | 354.18M |
| Q1 FY2019 | 31 Mar 2019 | 354.18M | — | 354.18M |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,Net income,EPS,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement
Common questions about Royalty Pharma's shares
Source: Financial Modeling Prep